Somnolence

Sleep Number Presents Research on Snoring, Apnea, Excessive Daytime Sleepiness and Cardiovascular Health at SLEEP 2024

Retrieved on: 
Donnerstag, Mai 30, 2024
Home Goods, Retail, Research, Oncology, Software, Online Retail, Hardware, Luxury, Professional Services, Fitness & Nutrition, Consumer Electronics, Science, Technology, General Health, Data Analytics, Health, HVAC, Specialty, Snoring, Sleep, Data collection, University, Obstructive sleep apnea, Risk, Sleep Number, Somnolence, Sleep disorder, HR, Sleep apnea, OSA, Narcolepsy, Mortality, Apnea, American Cancer Society, Bed, Multimedia, IRB, Pharmaceutical industry

Today, Sleep Number Corporation (Nasdaq: SNBR), a sleep wellness technology leader, announced it will present new research at SLEEP 2024 in Houston.

Key Points: 
  • Today, Sleep Number Corporation (Nasdaq: SNBR), a sleep wellness technology leader, announced it will present new research at SLEEP 2024 in Houston.
  • These studies further demonstrate the research capabilities of Sleep Number smart beds to understand the impact of sleep on health and advance sleep science without an in-lab sleep study.
  • (Graphic: Business Wire)
    “Sleep Number is continuously introducing data-driven approaches for improved sleep and health care outcomes,” said Annie Bloomquist, Executive Vice President and Chief Innovation Officer, Sleep Number.
  • "Sleep Number continues to be at the forefront of sleep research, harnessing the power of our wellness technology to uncover new links between sleep and overall health,” said Rajasi Mills, Vice President, SleepIQ Health and Research, Sleep Number.

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

Retrieved on: 
Mittwoch, Mai 29, 2024
Epilepsy, American Academy, Doctor of Philosophy, SHARP, Memory, Somnolence, University, AASM, Therapy, Sleep Research Society, Assistant, Excessive daytime sleepiness, Sleep, OSA, CNS, EDS, Washington State University, Central nervous system, SRS, Cognition, Function (mathematics), Central Time

“Cognitive functioning is an underappreciated facet of sleep disorders.

Key Points: 
  • “Cognitive functioning is an underappreciated facet of sleep disorders.
  • Often overshadowed by clinically defining symptoms such as EDS, impaired cognition involves significant burden to patient lives.
  • The SHARP study of solriamfetol showed improved cognitive functioning in participants with impaired cognition associated with OSA and EDS,” said Hans Van Dongen, PhD, Professor at Washington State University and presenting author of the SHARP study plenary lecture.
  • Poster Date/Time: Wednesday, June 5 from 11-11:45 a.m. Central Time
    Title: SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes

System Improves Trucker Safety, Wins Stella Zhang New Venture Competition Grand Prize at UCI

Retrieved on: 
Dienstag, Mai 28, 2024
Finance, Professional Services, Small Business, University, Education, Sentinel, Crafty, Machine learning, Privacy, Perseverance, Distracted driving, Entrepreneurship, Somnolence, Innovation, Motion, Multimedia, Mobile phone

An AI-enhanced system that watches over truck drivers and warns them when they are drowsy or distracted – without violating their privacy – took the top prize at the Stella Zhang New Venture Competition Grand Finale at the UCI Paul Merage School of Business.

Key Points: 
  • An AI-enhanced system that watches over truck drivers and warns them when they are drowsy or distracted – without violating their privacy – took the top prize at the Stella Zhang New Venture Competition Grand Finale at the UCI Paul Merage School of Business.
  • View the full release here: https://www.businesswire.com/news/home/20240528246919/en/
    The Sentinel team took home the $20,000 grand prize in addition to $10,000 for winning the Business Products and Services category in the 20th annual New Venture Competition.
  • (Photo: Business Wire)
    The Sentinel team took home the $20,000 grand prize in addition to $10,000 for winning the Business Products and Services category in the 20th annual New Venture Competition – the third with Stella Zhang as the title sponsor.
  • The Stella Zhang New Venture Competition is organized by the Beall Center for Innovation and Entrepreneurship.

Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

Retrieved on: 
Donnerstag, Mai 23, 2024
Insomnia, Patient, Diarrhea, Headache, Seizure, Nausea, Trial of the century, Dizziness, Safety, Event, Irritability, Epilepsy, Appetite, CNS, Fatigue, Somnolence, Aes, Webcast, Vomiting, Central nervous system, Drug

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced data from the planned interim analysis of the exploratory open-label Phase 2a clinical study of SPN-817 for treatment-resistant seizures. The study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant seizure types. The interim analysis is as of May 1, 2024, and is based on 41 enrolled subjects, of which 19 completed the maintenance period. Of these 19 subjects, 16 subjects had focal seizures.

Key Points: 
  • 86% median focal seizure reduction at the 3mg to 4mg twice daily doses in the open label extension period.
  • Responder analysis across all doses in maintenance period:
    81% of subjects with focal seizures had 30% or more seizure reduction.
  • “This planned interim analysis of our Phase 2a clinical study provides early, yet what seems to be strong evidence, of the clinical utility of SPN-817 in epilepsy.
  • We will extend the current Phase 2a study to explore potential approaches that we have identified to further improve the tolerability during titration.

Motive Brings AI-powered Safety, Security and Fleet Management Solution to Mexico

Retrieved on: 
Donnerstag, Mai 16, 2024
Fleet Management, Software, Automotive, Artificial Intelligence, Data Management, Trucking, Technology, Transport, OEM, Mobile, Computer, Zscaler, Accident, Risk, Fleet management, IBM, Safety, Health, Somnolence

Businesses across the country now have access to Motive’s integrated suite of driver safety, fleet management, theft prevention, and equipment monitoring solutions.

Key Points: 
  • Businesses across the country now have access to Motive’s integrated suite of driver safety, fleet management, theft prevention, and equipment monitoring solutions.
  • Motive welcomes Omar Camacho as General Manager for Mexico and head of the company’s new Mexico City office.
  • Fleet Management: Motive gives customers unparalleled visibility into the location, utilization and health of their vehicles and automates major operational workflows for fleet managers, dispatchers and maintenance teams.
  • Motive will showcase its products at several upcoming events in Mexico, including:

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Montag, Mai 6, 2024
Shift, Migraine, FDA, Agitation, Research, EMERGE, Webcast, CNS, Prescription, Reboxetine, Privacy, Medicine, BED, Obstructive sleep apnea, Fibromyalgia, Shift work, Deficit spending, Food, Sleep, System, ADHD, SWD, SYMPHONY, NT1, Therapy, Quality of life, Food and Drug Administration, MDD, Narcolepsy Network, Shirin David, Patient, Somnolence, FOCUS, Safety, Depression, CGRP, Binge eating disorder, Medicare, Cataplexy, Central nervous system, Government, DSM-IV codes, Clinical trial, EDS, NDA, NMDA, GPO, Psychiatry, MD, Idiopathic hypersomnia, Smoking, CMAI, Pivotal, Breakthrough therapy, Growth, Pharmaceutical industry

Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.

Key Points: 
  • Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.
  • Total cost of revenue was $6.3 million for the first quarter of 2024.
  • Research and development (R&D) expenses were $36.8 million for the first quarter of 2024, compared to $17.8 million for the comparable period in 2023, respectively.
  • Approximately 95,000 prescriptions were written for Auvelity in the first quarter of 2024, representing a 12% sequential increase versus the fourth quarter of 2023.

Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
Donnerstag, Mai 9, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, Annual general meeting, Therapy, Port, Somnolence, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • Our proprietary Glyph™ platform allows SPT-300 to be absorbed like a dietary fat through the intestinal lymphatic system and transported into circulation.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
Donnerstag, Mai 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, Human, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, PRTC, Annual general meeting, Therapy, Somnolence, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • The most common treatment-emergent adverse event was somnolence (29% SPT-300 vs. 13% placebo), which was transient and mild or moderate.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024

Retrieved on: 
Donnerstag, April 25, 2024
Somnolence, CHESS, ResMed, Webcast, Software as a service, CDI, PAP, Australian Securities Exchange, Sleep, Growth, F40, Video game

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024.

Key Points: 
  • Revenue in Europe, Asia, and other markets, excluding Software-as-a-Service, grew by 3 percent on a constant currency basis.
  • SG&A expenses improved to 19.2 percent of revenue in the quarter, compared with 20.5 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 8, 2024, through May 9, 2024, inclusive.
  • ResMed will discuss its third quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today.

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
Dienstag, April 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.